
|Articles|September 1, 2001
- Pharmaceutical Executive-09-01-2001
- Volume 0
- Issue 0
Profits and Promotion Under Attack
As policy makers struggle to devise a pharmacy benefit for Medicare patients, pressure mounts to impose spending limits on medications. In turn, consumer activists are challenging industry’s longtime claim that price controls will reduce investment in R&D for life-saving therapies.
Advertisement
Articles in this issue
over 24 years ago
New Playing Fieldsover 24 years ago
Inefficiencies: Cutting Through the Jungleover 24 years ago
Legislation: EC Proposes Changesover 24 years ago
Flexing Their Budgets: Big Pharma Spend Trendsover 24 years ago
Media Mix Town Meeting 2001: Much Ado About MediaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs
4
Pharmaceutical Executive Daily: FDA Approves Breztri
5




